Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.63 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | HTR7 | P34969 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4507337 | 0.92 | SIRT6 (0.60) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL1045292 | 0.84 | SIRT6 (0.69) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL12431530 | 0.82 | MAPT (0.70) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL9385628 | 0.81 | HTR7 (0.53) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL6945690 | 0.81 | SIRT6 (0.65) | SIRT6LMNAHTR7MAPTALDH1A1 | |
| SCHEMBL4820552 | 0.81 | SIRT6 (0.64) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL4628534 | 0.81 | SIRT6 (0.64) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL15599506 | 0.81 | POLB (0.64) | SIRT6LMNAMAPTALDH1A1HTR1A | |
| SCHEMBL2717022 | 0.81 | SIRT6 (0.64) | SIRT6LMNAMAPTHTR1APOLB | |
| SCHEMBL4248033 | 0.81 | SIRT6 (0.64) | SIRT6LMNAMAPTALDH1A1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113614087-B | WEE1 inhibitor and preparation and application thereof | 首药控股(北京)股份有限公司 | 2023-06-02 | — | — | CN | disclosed |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (beijing) Co., Ltd. (CN) | 2022-06-23 | — | — | US | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3943496-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | Shouyao Holdings (Beijing) Co., Ltd. (CN) | 2022-01-26 | — | — | EP | disclosed |
| CN-113614087-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)股份有限公司 | 2021-11-05 | — | — | CN | disclosed |
| CN-112724144-A | WEE1 inhibitor, and preparation and application thereof | 首药控股(北京)有限公司 | 2021-04-30 | — | — | CN | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2020192581-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | 首药控股(北京)有限公司 | 2020-10-01 | — | — | WO | disclosed |
| WO-2017211216-A1 | FUSED PYRIMIDINOPIPERIDINE DERIVATIVE, AND MANUFACTURING METHOD AND APPLICATION THEREOF | 上海艾力斯医药科技有限公司 | 2017-12-14 | — | — | WO | disclosed |
| EP-2681221-B1 | TRICYCLIC INHIBITORS OF KINASES | ABBVIE INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-8710065-B2 | Tricyclic inhibitors of kinases | ABBVIE INC. (US) | 2014-04-29 | — | — | US | disclosed |
| EP-2681221-A1 | TRICYCLIC INHIBITORS OF KINASES | AbbVie Inc. (US) | 2014-01-08 | — | — | EP | disclosed |
| WO-2012161812-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-11-29 | — | — | WO | disclosed |
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220572-A1 | TRICYCLIC INHIBITORS OF KINASES | WEE1, WEE2, CDK1 | SIRT6 3016/4885LMNA 3229/4885HTR7 4221/4885 |
| US-20220194960-A1 | WEE1 INHIBITOR AND PREPARATION AND USE THEREOF | WEE1, WEE2, RCE1 | SIRT6 1996/4885LMNA 1570/4885HTR7 4517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.